- call +1-201-465-4211
- email sales@mrinsights.biz
Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway. Treatment is limited to supportive care, including oxygen therapy and more advanced breathing support with CPAP or nasal high flow oxygen.
Scope of the Report:
This report focuses on the Human Respiratory Syncytial Virus Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period.
The active participation of emerging economies toward research and development will drive the growth prospects for the market during the forecast period. The increasing R&D activities in emerging economies for RSV infection and its causes will fuel the development of novel drugs. One of the major factors responsible for the market’s growth is the rising amount of patented therapies for RSV treatment that result in substantial R&D activities from various big pharma companies and research institutes. For instance, in June 2016, the Lancet Respiratory Medicine reported that RSV was the most commonly detected pathogen linked with pneumonia among children in South Africa. Such new findings will increase the scope of anti-RSV drugs in new applications, such as pneumonia.
ROW accounted for the maximum market share during 2017 and continue to dominate the market for the next few years. One of the major factors responsible for the market’s growth in the region is the growing incidence of RSV infections in ROW, including the BRIC nations.
The worldwide market for Human Respiratory Syncytial Virus Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
AstraZeneca
AbbVie
GSK
Teva Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Approved Drugs
Off-Label Drugs
Market Segment by Applications, can be divided into
Clinical Diagnostic
Laboratories Physicians' Office
Laboratories Hospitals
There are 15 Chapters to deeply display the global Human Respiratory Syncytial Virus Drugs market.
Chapter 1, to describe Human Respiratory Syncytial Virus Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Human Respiratory Syncytial Virus Drugs, with sales, revenue, and price of Human Respiratory Syncytial Virus Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Human Respiratory Syncytial Virus Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Human Respiratory Syncytial Virus Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Human Respiratory Syncytial Virus Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Human Respiratory Syncytial Virus Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Approved Drugs
1.2.2 Off-Label Drugs
1.3 Market Analysis by Applications
1.3.1 Clinical Diagnostic
1.3.2 Laboratories Physicians' Office
1.3.3 Laboratories Hospitals
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 Business Overview
2.1.2 Human Respiratory Syncytial Virus Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca Human Respiratory Syncytial Virus Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 AbbVie
2.2.1 Business Overview
2.2.2 Human Respiratory Syncytial Virus Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AbbVie Human Respiratory Syncytial Virus Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 GSK
2.3.1 Business Overview
2.3.2 Human Respiratory Syncytial Virus Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 GSK Human Respiratory Syncytial Virus Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Teva Pharmaceutical
2.4.1 Business Overview
2.4.2 Human Respiratory Syncytial Virus Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Teva Pharmaceutical Human Respiratory Syncytial Virus Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Human Respiratory Syncytial Virus Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Human Respiratory Syncytial Virus Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Human Respiratory Syncytial Virus Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Human Respiratory Syncytial Virus Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Human Respiratory Syncytial Virus Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Human Respiratory Syncytial Virus Drugs Market Analysis by Regions
4.1 Global Human Respiratory Syncytial Virus Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Human Respiratory Syncytial Virus Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Human Respiratory Syncytial Virus Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
4.5 South America Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
5 North America Human Respiratory Syncytial Virus Drugs by Countries
5.1 North America Human Respiratory Syncytial Virus Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Human Respiratory Syncytial Virus Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Human Respiratory Syncytial Virus Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
6 Europe Human Respiratory Syncytial Virus Drugs by Countries
6.1 Europe Human Respiratory Syncytial Virus Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Human Respiratory Syncytial Virus Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Human Respiratory Syncytial Virus Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
6.3 UK Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
6.4 France Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Human Respiratory Syncytial Virus Drugs by Countries
7.1 Asia-Pacific Human Respiratory Syncytial Virus Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Human Respiratory Syncytial Virus Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Human Respiratory Syncytial Virus Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
7.5 India Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
8 South America Human Respiratory Syncytial Virus Drugs by Countries
8.1 South America Human Respiratory Syncytial Virus Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Human Respiratory Syncytial Virus Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Human Respiratory Syncytial Virus Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Human Respiratory Syncytial Virus Drugs by Countries
9.1 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Human Respiratory Syncytial Virus Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Human Respiratory Syncytial Virus Drugs Sales and Growth Rate (2013-2018)
10 Global Human Respiratory Syncytial Virus Drugs Market Segment by Type
10.1 Global Human Respiratory Syncytial Virus Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Human Respiratory Syncytial Virus Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Human Respiratory Syncytial Virus Drugs Revenue and Market Share by Type (2013-2018)
10.2 Approved Drugs Sales Growth and Price
10.2.1 Global Approved Drugs Sales Growth (2013-2018)
10.2.2 Global Approved Drugs Price (2013-2018)
10.3 Off-Label Drugs Sales Growth and Price
10.3.1 Global Off-Label Drugs Sales Growth (2013-2018)
10.3.2 Global Off-Label Drugs Price (2013-2018)
11 Global Human Respiratory Syncytial Virus Drugs Market Segment by Application
11.1 Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Application (2013-2018)
11.2 Clinical Diagnostic Sales Growth (2013-2018)
11.3 Laboratories Physicians' Office Sales Growth (2013-2018)
11.4 Laboratories Hospitals Sales Growth (2013-2018)
12 Human Respiratory Syncytial Virus Drugs Market Forecast (2018-2023)
12.1 Global Human Respiratory Syncytial Virus Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Human Respiratory Syncytial Virus Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Human Respiratory Syncytial Virus Drugs Market Forecast (2018-2023)
12.2.2 Europe Human Respiratory Syncytial Virus Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Human Respiratory Syncytial Virus Drugs Market Forecast (2018-2023)
12.2.4 South America Human Respiratory Syncytial Virus Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Human Respiratory Syncytial Virus Drugs Market Forecast (2018-2023)
12.3 Human Respiratory Syncytial Virus Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Human Respiratory Syncytial Virus Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Human Respiratory Syncytial Virus Drugs Market Share Forecast by Type (2018-2023)
12.4 Human Respiratory Syncytial Virus Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Human Respiratory Syncytial Virus Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Human Respiratory Syncytial Virus Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Human Respiratory Syncytial Virus Drugs Picture
Table Product Specifications of Human Respiratory Syncytial Virus Drugs
Figure Global Sales Market Share of Human Res
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
